To identify candidate therapeutics, scientists developed an in vitro dilated cardiomyopathy model using induced pluripotent stem cell-derived cardiomyocytes deficient in B-cell lymphoma 2-associated athanogene 3 (BAG3).
[Science Translational Medicine]